Home › SYNDAX AND MERCK ANNOUNCE FIRST PATIENTS DOSED IN PHASE 1b/2 CLINICAL TRIAL OF ENTINOSTAT AND KEYTRUDA
 

Keywords :   


SYNDAX AND MERCK ANNOUNCE FIRST PATIENTS DOSED IN PHASE 1b/2 CLINICAL TRIAL OF ENTINOSTAT AND KEYTRUDA

2015-09-28 14:00:56| Merck.com - Product News

Dateline City: WALTHAM, Mass. and KENILWORTH, N.J. Clinical trial to assess safety and efficacy of immuno-oncology combination in patients with advanced NSCLC or melanoma WALTHAM, Mass. and KENILWORTH, N.J. Syndax Pharmaceuticals, Inc. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the dosing of the first patients in the Phase 1b/2 clinical trial of Syndaxs entinostat in combination with Mercks anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with non-small cell lung cancer (NSCLC) or melanoma. Language: English read more

Tags: of trial phase patients

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
13.05Melinda French Gates to quit Gates Foundation
13.05BASF in South Carolina Joins with Make-A-Wish
13.05PCMC addresses latest printing trends at \'Power Packs Live\'
13.05More than 50 sessions scheduled for drupa cube
13.05IDENTCO highlights automation and PCB labeling at PCB East
13.05Piracy on social media and messaging apps grows in Asia Pacific
13.05Anoki launches AI-powered experience on Google TV
13.05INDA, AFS Partner on FiltXPO 2025 Conference Program
More »